No signal was created. All models' risk/reward ratios were below the 1.5:1 minimum.
Market entry R:R was 1.33:1 (minimum 1.5:1)
All three models highlight LLY's strong Q1 2026 earnings beat, raised guidance, and the successful launch of Foundayo as primary catalysts, bolstered by a proposed FDA rule against compounded 'copycat' drugs. Technically, the stock maintains a bullish structure above the $999.36 support shelf and key moving averages, with two models targeting a retest of $1027 resistance within 1-3 weeks. Unique drivers include a new oral GLP-1 launch and significant infrastructure investment in Indiana.
All three models warn of momentum exhaustion and a failed-extension pattern as price stalls at the $1012 resistance with falling RSI and decelerating MACD histograms. Two models emphasize that the earnings beat is already priced in and note that depressed volume suggests a lack of conviction, potentially leading to a mean reversion toward the $940s or $900 support. A unique macro overhang involving the Trump-Xi summit and a hawkish Fed is cited as a catalyst for imminent profit-taking.
LLY still has a credible long swing case because the company just delivered another major earnings and revenue beat, raised 2026 guidance, is ramping a new oral GLP-1 launch, and has an incremental regulatory tailwind from the FDA proposal against copycat compounded products. Technically, price is holding above rising 4h and 1d moving averages and just above the $999-$1004 support shelf, so a controlled retest entry offers a way to participate if the post-earnings repricing resumes and pushes through the thin low-volume area around $1009-$1019 toward a retest of the $1027 daily resistance and then higher over the next 1-3 weeks.
LLY looks like a weak short setup into nearby resistance after a strong earnings-driven repricing left price pressing a 4h/30m supply zone around $1010- $1012 while short-term momentum is rolling over. On both 4h and daily charts RSI remains elevated but falling and MACD histograms are still positive yet decelerating, which fits a catalyst-exhaustion/failed-extension pattern rather than fresh breakout acceptance. If the stock cannot clear this first adverse barrier, a swing retracement back toward the upper value-area/high-volume region near the mid- $940s over the next 1-3 weeks is plausible, especially with depressed volume and a high-impact macro event inside a day increasing odds of mean reversion rather than trend continuation.
LLY presents a compelling long opportunity following its Q1 2026 blowout earnings and raised guidance, which reflect sustained dominance in the GLP-1 obesity market and strong momentum in Foundayo's launch. Despite near-term resistance at $1012 and a bearish macro regime, the stock is holding above key 4h support at $999.36 with bullish technical structure intact, including price trading above both SMA20 and SMA50 on the 4h chart. The combination of robust fundamental catalysts, resilient price action, and a favorable reward-to-risk setup supports a swing long entry at current levels targeting a retest of the 1-day resistance at $1027.00.
Eli Lilly is extended at resistance with deteriorating momentum despite strong recent earnings, creating a high-probability reversal setup. Price is stalling just below the 4h resistance at $1012 with a falling RSI and contracting MACD histogram, while volume remains depressed, suggesting lack of conviction in the rally. The upcoming macro overhang from the Trump-Xi summit and hawkish Fed seating creates a risk-off environment that could trigger profit-taking in richly valued names like LLY, driving a retest of $900 support.
Eli Lilly's strong Q1 earnings and successful product launches, such as Foundayo, position the company for continued growth. The recent investment in Indiana and proposed FDA rule to prohibit compounding facilities from producing 'copycat' versions of key incretin drugs are expected to drive momentum. With a technically sound setup and favorable macro context, LLY is poised for a long trade.
The current price of LLY is extended at resistance and shows signs of momentum exhaustion. The recent earnings beat and guidance raise have already been priced in, and the stock is due for a pullback. The technical structure, including the RSI and MACD, confirms this thesis.